References

cardiotomsk

Сибирский журнал клинической и экспериментальной медицины

Siberian Journal of Clinical and Experimental Medicine

2713-29272713-265X

TSU publishing

10.29001/2073-8552-2016-31-3-7-15

cardiotomsk-221

Research Article

ОБЗОРЫ И ЛЕКЦИИ

REVIEWS AND LECTURES

С-JUN N-ТЕРМИНАЛЬНЫЕ КИНАЗЫ И ИХ МОДУЛЯТОРЫ ПРИ ИШЕМИЧЕСКИ– РЕПЕРФУЗИОННОМ ПОВРЕЖДЕНИИ МИОКАРДА (ОБЗОР ЛИТЕРАТУРЫ)

С-JUN N-TERMINAL KINASES AND THEIR MODULATORS IN MYOCARDIAL ISCHEMIA/REPERFUSION INJURY (REVIEW)

Шведова

М. В.

Shvedova

M. V.

канд. мед. наук, врач-хирург клиники госпитальной хирургии;

младший научный сотрудник,

634028, г. Томск, пр. Ленина, 4

Tomsk

shvedovamv55@gmail.com

Анфиногенова

Я. Д.

Anfinogenova

докт. мед. наук, ведущий научный сотрудник отделения популяционной кардиологии с группой научно-медицинской информации, патентоведения и международных связей;

научный сотрудник;

профессор кафедры нормальной физиологии,

634012, г. Томск, ул. Киевская, 111а

Tomsk

ya@cardio-tomsk.ru

Попов

С. В.

Popov

S. V.

докт. мед. наук, профессор, член-корреспондент РАН, заслуженный деятель науки РФ; директор,

634012, г. Томск, ул. Киевская, 111а

psv@cardio-tomsk.ru

Щепеткин

И. А.

Shchepetkin

I. A.

ведущий научный сотрудник;

канд. мед. наук, старший научный сотрудник Отдела микробиологии и иммунологии,

960 Technology Blvd., Department of Microbiology and Immunology, Montana State University, Bozeman, Montana 59715, USA

Tomsk;

Bozeman, Montana, USA

igor@montana.edu

Аточин

Д. Н.

Atochin

D. N.

заведующий лабораторией изучения механизмов нейропротекции;

канд. биол. наук, Assistant Professor in Medicine, Cardiology Division, Cardiovascular Research Center,

149 13th Street, 4th Floor, Charlestown, MA 02129

Tomsk;

Charlestown, Massachusetts, USA

atochin@cvrc.mgh.harvard.edu

Федеральное государственное бюджетное образовательное учреждение высшего образования “Сибирский государственный медицинский университет” Министерства здравоохранения Российской Федерации; Центр RASA в Томске, Федеральное государственное автономное образовательное учреждение высшего образования “Национальный исследовательский Томский политехнический университет”РоссияRASA Center in Tomsk, Tomsk Polytechnic University; Siberian State Medical UniversityRussian Federation

Научно-исследовательский институт кардиологии, Томский национальный исследовательский медицинский центр Российской академии наук; Центр RASA в Томске, Федеральное государственное автономное образовательное учреждение высшего образования “Национальный исследовательский Томский политехнический университет” Центр RASA ФГАОУ ВО НИ ТПУ; Федеральное государственное бюджетное образовательное учреждение высшего образования “Сибирский государственный медицинский университет” Министерства здравоохранения Российской Федерации ФГБОУ ВО СибГМУ Минздрава РоссииРоссияRASA Center in Tomsk, Tomsk Polytechnic University; Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences; Siberian State Medical UniversityRussian Federation

Научно-исследовательский институт кардиологии, Томский национальный исследовательский медицинский центр Российской академии наукРоссияCardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of SciencesRussian Federation

Центр RASA в Томске, Федеральное государственное автономное образовательное учреждение высшего образования “Национальный исследовательский Томский политехнический университет”; Отдел микробиологии и иммунологии, университет штата МонтанаРоссияRASA Center in Tomsk, Tomsk Polytechnic University; Department of Microbiology and Immunology, Montana State UniversityRussian Federation

Центр RASA в Томске, Федеральное государственное автономное образовательное учреждение высшего образования “Национальный исследовательский Томский политехнический университет”; Центр сердечно-сосудистых исследований и Отдел кардиологии, Главный госпиталь Массачусетса, Гарвардская медицинская школаРоссияRASA Center in Tomsk, Tomsk Polytechnic University; Cardiovascular Research Center, Cardiology Division, Massachusetts General Hospital, Harvard Medical SchoolRussian Federation

2016

04112016

313715

2016

Шведова М.В., Анфиногенова Я.Д., Попов С.В., Щепеткин И.А., Аточин Д.Н.

Shvedova M.V., Anfinogenova Y., Popov S.V., Shchepetkin I.A., Atochin D.N.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.sibjcem.ru/jour/article/view/221

Представлен обзор литературы, посвященный роли с Jun N терминальных киназ (JNK) в ишемически реперфу зионном повреждении миокарда. Дана классификация JNK, описаны их функции в сигнальныx механизмax, вовлеченныx в повреждение миокарда при ишемии и реперфузии. Авторы обсуждают биологические эффекты фармакологической модуляции JNK с использованием синтетических и природных соединений в эксперимен тальных моделях ишемически реперфузионного поражения миокарда. Подчеркивается роль JNK в механизмах ишемического пре и посткондиционирования сердца. Результаты экспериментальных исследований показыва ют, что JNK представляют собой потенциальные терапевтические мишени для защиты сердца от ишемически– реперфузионного повреждения. В то же время наличие многочисленных физиологических функций JNK не по зволяет системно использовать неспецифические ингибиторы этих ферментов с терапевтической целью. Авторы заключают, что актуальной задачей остается дальнейший поиск селективных ингибиторов JNK3.

The article provides review of literature on the role of c Jun N terminal kinases (JNK) in ischemia/reperfusion injury of the myocardium. The classification of JNK is presented; JNK functions in signaling mechanisms are described in the context of ischemia/reperfusion injury. Authors discuss biological effects of pharmacological modulation of JNK by using synthetic and natural compounds in the models of myocardial ischemia/reperfusion. The role of JNK in the mechanisms of pre and postconditioning of the heart is highlighted. Results of experimental studies are demonstrated that JNK represent potential therapeutic targets for cardiac protection from ischemia/reperfusion injury. At the same time, the presence of multiple physiological JNK properties does not allow for systemic use of non specific JNK inhibitors for therapeutic purposes. Authors conclude that the actual problem is the further search for selective JNK3 inhibitors.

апоптозc-Jun-N терминальная киназаингибитор JNKишемически–реперфузионное повреждениемиокардтерапевтическая мишень

apoptosisc-Jun-N terminal kinaseJNK inhibitorischemia/reperfusion injurymyocardiumtherapeutic target

государственное задание “Наука”

References1

Влаопулос С., Зумпурлис В.С. JNK: ключевой модулятор внутриклеточной сигнальной системы // Биохимия. – 2004. – № 69(8). – С. 1038–1050.

Зюзьков Г.Н., Жданов В.В., Удут Е.В. и др. Роль JNK и участие p53 в реализации ростового потенциала мезенхимных клеток предшественников в условиях in vitro // Бюллетень экспериментальной биологии и медицины. – 2015. – № 159(2). – С. 205–208.

Маслов Л.Н., Мрочек А.Г., Щепёткин И.А. и др. Роль протеинкиназ в формировании адаптивного феномена ишемического посткондиционирования сердца // Рос. физиологический журнал им. И.М. Сеченова. – 2013. – № 99(4). – С. 433–452.

Рязанцева Н.В., Новицкий В.В., Часовских Н.Ю. и др. Роль редокс зависимых сигнальных систем в регуляции апоптоза при окислительном стрессе // Цитология. – 2009. – № 51(4). – С. 329–334.

Aoki H., Kang P.M., Hampe J. et al. Direct activation of mitochondrial apoptosis machinery by c Jun N terminal kinase in adult cardiac myocytes // J. Biol. Chem. – 2002. – Vol. 277(12). – P. 10244–10250.

Armstrong S.C. Protein kinase activation and myocardial ischemia/reperfusion injury // Cardiovasc. Res. – 2004. – Vol. 61(3). – P. 427–436.

Arslan F., Lai R.C., Smeets M.B. et al. Mesenchymal stem cell derived exosomes increase ATP levels, decrease oxidative stress and activate PI3K/Akt pathway to enhance myocardial viability and prevent adverse remodeling after myocardial ischemia/ reperfusion injury // Stem Cell Res. – 2013. – Vol. 10(3). – P. 301–312.

Atochin D.N., Schepetkin I.A., Khlebnikov A.I. et al. A novel dual NO donating oxime and c Jun N terminal kinase inhibitor protects against cerebral ischemia reperfusion injury in mice // Neurosci. Lett. – 2016. – Vol. 618. – P. 45–49.

Barancik M., Htun P., Schaper W. Okadaic acid and anisomycin are protective and stimulate the SAPK/JNK pathway // J. Cardiovasc. Pharmacol. – 1999. – Vol. 34(2). – P. 182–190.

Becatti M., Taddei N., Cecchi C. et al. SIRT1 modulates MAPK pathways in ischemic reperfused cardiomyocytes // Cell. Mol. Life Sci. – 2012. – Vol. 69(13). – P. 2245–2260.

Bode A.M., Dong Z. The functional contrariety of JNK // Mol. Carcinog. – 2007. – Vol. 46(8). – P. 591–598.

Bogoyevitch M.A., Kobe B. Uses for JNK: the many and varied substrates of the c-Jun-N-terminal kinases // Microbiol. Mol. Biol. Rev. – 2006. – Vol. 70(4). – P. 1061–1095.

Chambers J.W., Pachori A., Howard S. et al. Inhibition of JNK mitochondrial localization and signaling is protective against ischemia/reperfusion injury in rats // J. Biol. Chem. – 2013. – Vol. 288(6). – P. 4000–4011.

Chaudhury H., Zakkar M., Boyle J. et al. C-Jun-N terminal kinase primes endothelial cells at atheroprone sites for apoptosis // Arterioscler. Thromb. Vasc. Biol. – 2010. – Vol. 30(3). – P. 546–553.

Chen Y.C., Jinn T.R., Chung T.Y. et al. Magnesium lithospermate B extracted from Salvia miltiorrhiza elevates intracellular Ca2+ level in SH SY5Y cells // Acta Pharmacol. Sin. – 2010. – Vol. 31(8). – P. 923–929.

Clerk A., Fuller S.J., Michael A. et al. Stimulation of “stress-regulated” mitogen-activated protein kinases (stress-activated protein kinases/c-Jun-N-terminal kinases and p38 mitogen-activated protein kinases) in perfused rat hearts by oxidative and other stresses // J. Biol. Chem. – 1998. – Vol. 273(13). – P. 7228–7234.

Dougherty C.J., Kubasiak L.A., Frazier D.P. et al. Mitochondrial signals initiate the activation of c Jun N terminal kinase (JNK) by hypoxia-reoxygenation // FASEB J. – 2004. – Vol. 18(10). – P. 1060–1070.

Dougherty C.J., Kubasiak L.A., Prentice H. et al. Activation of c-Jun N-terminal kinase promotes survival of cardiac myocytes after oxidative stress // Biochem. J. – 2002. – Vol. 362 (Pt. 3). – P. 561–571.

Duplain H. Salvage of ischemic myocardium: a focus on JNK // Adv. Exp. Med. Biol. – 2006. – Vol. 588. – P. 157–164.

Engelbrecht A.M., Niesler C., Page C. et al. P38 and JNK have distinct regulatory functions on the development of apoptosis during simulated ischaemia and reperfusion in neonatal cardiomyocytes // Basic Res. Cardiol. – 2004. – Vol. 99(5). – P. 338–350.

Ferrandi C., Ballerio R., Gaillard P. et al. Inhibition of c-Jun N-terminal kinase decreases cardiomyocyte apoptosis and infarct size after myocardial ischemia and reperfusion in anaesthetized rats // Br. J. Pharmacol. – 2004. – Vol. 142(6). – P. 953–960.

Frazier D.P., Wilson A., Dougherty C.J. et al. PKC alpha and TAK-1 are intermediates in the activation of c-Jun NH2 terminal kinase by hypoxia reoxygenation // Am. J. Physiol. Heart Circ. Physiol. – 2007. – Vol. 292(4). – P. H1675–1684.

Fryer R.M., Patel H.H., Hsu A.K. et al. Stress activated protein-kinase phosphorylation during cardioprotection in the ischemic myocardium // Am. J. Physiol. Heart. Circ. Physiol. – 2001. – Vol. 281(3). – P. H1184–1192.

Gehringer M., Muth F., Koch P., Laufer S.A. c-Jun N-terminal kinase inhibitors: a patent review (2010–2014) // Expert Opin. Ther. Pat. – 2015. – Vol. 25(8). – P. 849–872.

Gupta S., Barrett T., Whitmarsh A.J. et al. Selective interaction of JNK protein kinase isoforms with transcription factors // The EMBO Journal. – 1996. – Vol. 15(11). – P. 2760–2770.

Hausenloy D.J., Yellon D.M. Survival kinases in ischemic preconditioning and postconditioning // Cardiovasc. Res. – 2006. – Vol. 70(2). – P. 240–253.

Hausenloy D.J., Yellon D.M. Preconditioning and postconditioning: united at reperfusion // Pharmacol. Ther. – 2007. – Vol. 116(2). – P. 173–191.

He H., Li H.L., Lin A. et al. Activation of the JNK pathway is important for cardiomyocyte death in response to simulated ischemia // Cell Death Differ. – 1999. – Vol. 6(10). – P. 987–991.

Hreniuk D., Garay M., Gaarde W. et al. Inhibition of c-Jun N-terminal kinase 1, but not c-Jun N-terminal kinase 2, suppresses apoptosis induced by ischemia/reoxygenation in rat cardiac myocytes // Mol. Pharmacol. – 2001. – Vol. 59(4). — P. 867–874.

Ip Y.T., Davis R.J. Signal transduction by the c-Jun N-terminal kinase (JNK) – from inflammation to development // Curr. Opin. Cell Biol. – 1998. – Vol. 10(2). – P. 205–219.

Irving E.A., Bamford M. Role of mitogen and stress-activated kinases in ischemic injury // J. Cereb. Blood Flow Metab. – 2002. – Vol. 22(6). – P. 631–647.

Jang S., Javadov S. Inhibition of JNK aggravates the recovery of rat hearts after global ischemia: the role of mitochondrial JNK // PLoS One. – 2014. – Vol. 9(11). – P. e113526.

Javadov S., Jang S., Agostini B. Crosstalk between mitogen-activated protein kinases and mitochondria in cardiac diseases: therapeutic perspectives // Pharmacol. Ther. – 2014. – Vol. 144(2). – P. 202–225.

Johnson G.L., Nakamura K. The c-jun kinase/stress-activated pathway: regulation, function and role in human disease // Biochim. Biophys. Acta. – 2007. – Vol. 1773(8). – P. 1341–1348.

Kaiser R.A., Liang Q., Bueno O. et al. Genetic inhibition or activation of JNK1/2 protects the myocardium from ischemia–reperfusion induced cell death in vivo // J. Biol. Chem. – 2005. – Vol. 280(38). – P. 32602–32608.

Khalid S., Drasche A., Thurner M. et al. c-Jun N-terminal kinase (JNK) phosphorylation of serine 36 is critical for p66Shc activation // Sci. Rep. – 2016. – Vol. 6. – P. 20930.

Khandoudi N., Delerive P., Berrebi-Bertrand I. et al. Rosiglitazone, a peroxisome proliferator activated receptor-gamma, inhibits the Jun NH(2) terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury // Diabetes. – 2002. – Vol. 51(5). – P. 1507–1514.

Knight R.J., Buxton D.B. Stimulation of c-Jun kinase and mitogen-activated protein kinase by ischemia and reperfusion in the perfused rat heart // Biochem. Biophys. Res. Commun. – 1996. – Vol. 218(1). – P. 83–88.

Laderoute K.R., Webster K.A. Hypoxia/reoxygenation stimulates Jun kinase activity through redox signaling in cardiac myocytes // Circ. Res. – 1997. – Vol. 80(3). – P. 336–344.

Li H.H., Du J., Fan Y.N. et al. The ubiquitin ligase MuRF1 protects against cardiac ischemia/reperfusion injury by its proteasome-dependent degradation of phospho c-Jun // Am. J. Pathol. – 2011. – Vol. 178(3). – P. 1043–1058.

Li C., Gao Y., Tian J. et al. Sophocarpine administration preserves myocardial function from ischemia reperfusion in rats via NF-кB inactivation // J. Ethnopharmacol. – 2011. – Vol. 135(3). – P. 620–625.

Li X.M., Ma Y.T., Yang Y.N. et al. Ischemic postconditioning protects hypertrophic myocardium by ERK1/2 signaling pathway: experiment with mice // Zhonghua Yi Xue Za Zhi. – 2009. – Vol. 89(12). – P. 846–850.

Li C., Wang T., Zhang C. et al. Quercetin attenuates cardiomyocyte apoptosis via inhibition of JNK and p38 mitogen activated protein kinase signaling pathways // Gene. – 2016. – Vol. 577(2). – P. 275–280.

Liu Q., Wang J., Liang Q. et al. Sparstolonin B attenuates hypoxia-reoxygenation induced cardiomyocyte inflammation // Exp. Biol. Med. (Maywood). – 2014. – Vol. 239(3). – P. 376–384.

Liu X., Xu F., Fu Y. et al. Calreticulin induces delayed cardioprotection through mitogen

activated protein kinases // Proteomics. – 2006. – Vol. 6(13). – P. 3792–3800.

Liu H.T., Zhang H.F., Si R. et al. Insulin protects isolated hearts from ischemia/reperfusion injury: cross talk between PI3-K/Akt and JNKs // Acta Physiol. Sin. – 2007. – Vol. 59(5). – P. 651–659.

Liu X.H., Zhang Z.Y., Sun S. et al. Ischemic postconditioning protects myocardium from ischemia/reperfusion injury through attenuating endoplasmic reticulum stress // Shock. – 2008. – Vol. 30(4). – P. 422–427.

Messoussi A., Feneyrolles C., Bros A. et al. Recent progress in the design, study, and development of c-Jun N-terminal kinase inhibitors as anticancer agents // Chem. Biol. – 2014. – Vol. 21(11). – P. 1433–1443.

Milano G., Morel S., Bonny C. et al. A peptide inhibitor of c-Jun NH2-terminal kinase reduces myocardial ischemia reperfusion injury and infarct size in vivo // Am. J. Physiol. Heart Circ. Physiol. – 2007. – Vol. 292(4). – P. H1828–1835.

Morrison A., Yan X., Tong C. et al. Acute rosiglitazone treatment is cardioprotective against ischemia reperfusion injury by modulating AMPK, Akt, and JNK signaling in nondiabetic mice // Am. J. Physiol. Heart Circ. Physiol. – 2011. – Vol. 301(3). – P. H895–902.

Nakano A., Baines C.P., Kim S.O. et al. Ischemic preconditioning activates MAPKAPK2 in the isolated rabbit heart: evidence for involvement of p38 MAPK // Circ. Res. – 2000. – Vol. 86(2). – P. 144–151.

Nijboer C.H., van der Kooij M.A., van Bel F. et al. Inhibition of the JNK/AP-1 pathway reduces neuronal death and improves behavioral outcome after neonatal hypoxic ischemic brain injury // Brain Behav. Immun. – 2010. – Vol. 24(5). – P. 812– 821.

Oshikawa J., Kim S.J., Furuta E. et al. Novel role of p66Shc in ROS-dependent VEGF signaling and angiogenesis in endothelial cells // Am. J. Physiol. Heart Circ. Physiol. – 2012. – Vol. 302(3). – P. H724–732.

Ping P., Zhang J., Huang S. et al. PKC-dependent activation of p46/p54 JNKs during ischemic preconditioning in conscious rabbits // Am. J. Physiol. – 1999. – Vol. 277(5 Pt. 2). – P. H1771–1785.

Qi D., Hu X., Wu X. et al. Cardiac macrophage migration inhibitory factor inhibits JNK pathway activation and injury during ischemia/reperfusion // J. Clin. Invest. – 2009. – Vol. 119(12). – P. 3807–3816.

Rose B.A., Force T., Wang Y. Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale // Physiol. Rev. – 2010. – Vol. 90(4). – P. 1507–1546.

Sato M., Bagchi D., Tosaki A. et al. Grape seed proanthocyanidin reduces cardiomyocyte apoptosis by inhibiting ischemia/reperfusion induced activation of JNK-1 and C-JUN // Free Radic. Biol. Med. – 2001. – Vol. 31(6). – P. 729–737.

Shang L., Ananthakrishnan R., Li Q. et al. RAGE modulates hypoxia/reoxygenation injury in adult murine cardiomyocytes via JNK and GSK-3beta signaling pathways // PLoS One. – 2010. – Vol. 5(4). – P. e10092.

Shao Z., Bhattacharya K., Hsich E. et al. c-Jun N-terminal kinases mediate reactivation of Akt and cardiomyocyte survival after hypoxic injury in vitro and in vivo // Circ. Res. – 2006. – Vol. 98(1). – P. 111–118.

Shi S., Li Q.S., Li H. et al. Anti-apoptotic action of hydrogen sulfide is associated with early JNK inhibition // Cell Biol. Int. – 2009. – Vol. 33(10). – P. 1095–1101.

Song Z.F., Ji X.P., Li X.X. et al. Inhibition of the activity of poly (ADP-ribose) polymerase reduces heart ischaemia/reperfusion injury via suppressing JNK-mediated AIF translocation // Cell Mol. Med. – 2008. – Vol. 12(4). – P. 1220–1228.

Sun L., Isaak C.K., Zhou Y. et al. Salidroside and tyrosol from Rhodiola protect H9c2 cells from ischemia/reperfusion induced-apoptosis // Life Sci. – 2012. – Vol. 91(5–6). – P. 151–158.

Sun H.Y., Wang N.P., Halkos M. et al. Postconditioning attenuates cardiomyocyte apoptosis via inhibition of JNK and p38 mitogen-activated protein kinase signaling pathways // Apoptosis. – 2006. – Vol. 11(9). – P. 1583–1593.

Talmor D., Applebaum A., Rudich A. et al. Activation of mitogen-activated protein kinases in human heart during cardiopulmonary bypass // Circ. Res. – 2000. – Vol. 86(9). – P. 1004–1007.

Vassalli G., Milano G., Moccetti T. Role of Mitogen-Activated Protein Kinases in myocardial ischemia reperfusion injury during heart transplantation // J. Transplant. – 2012. – Vol. 2012. – P. 928954.

Waetzig V., Herdegen T. Context-specific inhibition of JNKs: overcoming the dilemma of protection and damage // Trends Pharmacol. Sci. – 2005. – Vol. 26(9). – P. 455–461.

Walshe C.M., Laffey J.G., Kevin L. et al. Sepsis protects the myocardium and other organs from subsequent ischaemic/reperfusion injury via a MAPK dependent mechanism // Intensive Care Med. Exp. – 2015. – Vol. 3(1). – P. 35.

Wang Z., Huang H., He W. et al. Regulator of G-protein signaling 5 protects cardiomyocytes against apoptosis during in vitro cardiac ischemia-reperfusion in mice by inhibiting both JNK and P38 signaling pathways [Electronic resource] // Biochem. Biophys. Res. Commun. – 2016. – Vol. 473(2). – P. 551–557.

Wang J., Yang L., Rezaie A.R. et al. Activated protein C protects against myocardial ischemic/reperfusion injury through AMP-activated protein kinase signaling // J. Thromb. Haemost. – 2011. – Vol. 9(7). – P. 1308–1317.

Wei J., Wang W., Chopra I. et al. C-Jun N-terminal kinase (JNK-1) confers protection against brief but not extended ischemia during acute myocardial infarction // J. Biol. Chem. – 2011. – Vol. 286(16). – P. 13995–14006.

Wei C., Zhao Y., Wang L. et al. H2S restores the cardioprotection from ischemic post-conditioning in isolated aged rat hearts // Cell Biol. Int. – 2015. – Vol. 39(10). – P. 1173–1176.

Wiltshire C., Gillespie D.A., May G.H. Sab (SH3BP5), a novel mitochondria-localized JNK interacting protein // Biochem. Soc. Trans. – 2004. – Vol. 32 (Pt. 6). – P. 1075–1077.

Wu J., Li J., Zhang N. et al. Stem cell-based therapies in ischemic-heart diseases: a focus on aspects of microcirculation and inflammation // Basic Res. Cardiol. – 2011. – Vol. 106(3). – P. 317–324.

Xie P., Guo S., Fan Y. et al. Atrogin-1/MAFbx enhances simulated ischemia/reperfusion induced apoptosis in cardiomyocytes through degradation of MAPK phosphatase-1 and sustained JNK-activation // J. Biol. Chem. – 2009. – Vol. 284(9). – P. 5488–5496.

Xu J., Qin X., Cai X. et al. Mitochondrial JNK activation triggers autophagy and apoptosis and aggravates myocardial injury-following ischemia/reperfusion // Biochim. Biophys. Acta. – 2015. – Vol. 1852(2). – P. 262–270.

Xu T., Wu X., Chen Q. et al. The anti-apoptotic and cardioprotective effects of salvianolic acid A on rat cardiomyocytes following ischemia/reperfusion by DUSP-mediated regulation of the ERK1/2/JNK pathway // PLoS One. – 2014. – Vol. 9(7). – P. e102292.

Xu H., Yao Y., Su Z. et al. Endogenous HMGB1 contributes to ischemia reperfusion-induced myocardial apoptosis by potentiating the effect of TNF-alpha/JNK // Am. J. Physiol. Heart Circ. Physiol. – 2011. – Vol. 300(3). – P. H913–921.

Yang L.M., Xiao Y.L., Ou Yang J.H. Inhibition of magnesium lithospermate B on the c-Jun N-terminal kinase 3 mRNA-expression in cardiomyocytes encountered ischemia/reperfusion injury // Acta Pharmacol. Sin. – 2003. – Vol. 38(7). – P. 487–491.

Yin T., Sandhu G., Wolfgang C.D. et al. Tissue specific pattern of stress kinase activation in ischemic/reperfused heart and kidney // J. Biol. Chem. – 1997. – Vol. 272(32). – P. 19943–19950.

Yue T.L., Wang C., Gu J.L. et al. Inhibition of extracellular signal-regulated kinase enhances ischemia/reoxygenation induced apoptosis in cultured cardiac myocytes and exaggerates reperfusion injury in isolated perfused heart // Circ. Res. – 2000. – Vol. 86(6). – P. 692–699.

Zaha V.G., Qi D., Su K.N. et al. AMPK is critical for mitochondrial function during reperfusion after myocardial ischemia // J. Mol. Cell. Cardiol. – 2016. – Vol. 91. – P. 104–113.

Zhang J., Li X.X., Bian H.J. et al. Inhibition of the activity of Rho-kinase reduces cardiomyocyte apoptosis in heart ischemia/reperfusion via suppressing JNK-mediated AIF translocation // Clin. Chim. Acta. – 2009. – Vol. 401(1–2). – P. 76–80.

Zhang G.M., Wang Y., Li T.D. et al. Change of JNK MAPK and its influence on cardiocyte apoptosis in ischemic postconditioning // J. Zhejiang Univ. – 2009. – Vol. 38(6). – P. 611–619.

Zhang G.M., Wang Y., Li T.D. et al. Post conditioning with gradually increased reperfusion provides better cardioprotection in rats // World J. Emerg. Med. – 2014. – Vol. 5(2). – P. 128–134.

Zinkel S., Gross A., Yang E. BCL2 family in DNA damage and cell cycle control // Cell Death Differ. – 2006. – Vol. 13(8). – P. 1351–1359.

The authors declare that there are no conflicts of interest present.